Leica Biosystems expanded efforts to commercialize AI-driven oncology pathology tools via the Aperio AI Store by partnering with DiaDeep, a Lyon-based medical AI company. The reseller deal makes DiaDeep’s AI applications available within Leica’s digital pathology workflow. DiaDeep’s offerings integrate into Aperio HALO AP image management so pathologists can access automated quantification and analysis as a “copilot” without leaving established workflows. The partnership aims to support scalable adoption of AI for cancer diagnostics and research. For the market, the move indicates accelerating commercialization of image-analysis products—shifting AI from pilots into packaged tools that can be rolled out in routine pathology operations.